Novartis signs antibody licensing agreement with two biotechs

20-07-2018

Novartis signs antibody licensing agreement with two biotechs

oonal / iStockphoto.com

Novartis has signed a global licensing agreement with two biotechnology companies centring on the development of an antibody treatment for inflammatory skin conditions.


Novartis, MorphoSys, Galapagos, licensing agreement, inflammatory diseases, antibody, research and development, drug commercialisation, atopic dermatitis

LSIPR